|Name:||1-Phenanthrenecarboxylicacid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-,sodium salt (1;1), (1R,4aS,10aR)-|
|Formula:||C20H28O5S . Na|
|Synonyms:||1-Phenanthrenecarboxylicacid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-,monosodium salt, (1R,4aS,10aR)- (9CI);Gastrom;TA 2711;|
Please post your buying leads,so that our qualified suppliers
will soon contact you!
Ecabet sodium , with cas registry number of 86408-72-2, is classifed as Anti-infective agents and Gastrointestinal Agents. It is also called Ecabet sodium salt ; 12-Sulfodehydroabietic acid monosodium salt ; Sulfodehydroabietic acid monosodium salt ; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-, (1R-(1-alpha,4a-beta,10a-alpha))-, monosodium salt . Besides these names, it also has its own IUPAC name and systematic name which are Sodium (4bS,8R,8aR)-8-methoxycarbonyl-4b-methyl-2-propan-2-yl-6,7,8,8a,9,10-hexahydro-5H-phenanthrene-3-sulfonate and 12-Sulfoabieta-8(14),9(11),12-trien-18-oic acid . Ecabet sodium is soluble in water with solubility of 13.44 mg/L at 25 °C.
About its structure, its SMILES is O=S(=O)(O)c1c(cc2c(c1)[C@@]3([C@@H](CC2)[C@@](C(=O)O)(C)CCC3)C)C(C)C which is used to convert directly to the structure. There are also other information about its bonds which are H bond acceptors 5, H bond donors 2, and Freely Rotating Bonds 3.
In some reported patents, we can see the synthesis method about aqueous ecabet sodium solution. The reaction is in solution at a concentration of 1 w/v % or more of sulfodehydroabietic acid with the pH ranging from 7 to 8.5. And one pH buffer is selected from a salt of a polycarboxylic acid and a salt of a polyphoshoric acid, and an inorganic base.
In many studies, Ecabet sodium is found that it is a good anti-ulcer agent which has efficacy against Helicobacter pylori under acidic conditions. It has dual therapy with lansoprazole and amoxicillin. Some of its toxicity data has been studied showing in the table below:
|Organism||Test Type||Route||Reported Dose (Normalized Dose)||Effect||Source|
|dog||LD50||oral||> 2gm/kg (2000mg/kg)||Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 36, Pg. 667, 1994.|
|rat||LD50||oral||> 2gm/kg (2000mg/kg)||United States Patent Document. Vol. #4529602,|
|rat||LD50||subcutaneous||> 2gm/kg (2000mg/kg)||Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 36, Pg. 667, 1994.|